Alpback Workshop

MENU menu

8th Alpbach Workshop on
Affinity Proteomics
March 13-15 2017



Cambridge Protein Arrays Ltd are the exclusive European distributors and service providers for HuProt™ arrays, the largest human protein arrays available, with more than 19,000 human proteins, representing more than 15,000 human genes on a single slide. HuProt™ arrays are designed for screening of antibody specificity, autoimmune profiling, and protein interactions. Cambridge Protein Arrays Ltd. is a biotech SME founded in 2010 by Mike Taussig, located in Cambridge, UK. With strong roots in the European Affinity Proteomics community, we are also the organisers of the 8th Alpbach Workshop in Affinity Proteomics.

Cambridge Protein Arrays


Explore our extensive portfolio of more than 74,000 high-quality primary and secondary antibodies ( covering over 85% of the proteome, supported by an extensive range of antibody-related products and custom services. Our antibody assays are validated by thousands of citations worldwide, helping you achieve superior results in a wide range of detection and purification applications.



As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways. Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.


Atlas Antibodies develop, produce and market reagents for proteomic research. The products include thoroughly validated antibodies and labelled and unlabeled protein fragments for both qualitative and quantitative analysis of human proteins. The goal is to offer reagents targeting all human proteins and with more than 55,000 products, over 80% of all human proteins are currently covered. The products are marketed and sold both directly to end users worldwide and through several global and local distributors. Atlas Antibodies is a spin-out from the Swedish Human Protein Atlas (HPA) project and the majority of the research products have been developed by the HPA project for the purpose of creating a map of human protein expression and localization in normal tissues, cancers and cell lines.

Atlas Antibodies


Swedish company Olink Proteomics provides innovative solutions for targeted human protein biomarker discovery. Proseek® Multiplex enables rapid, high-throughput analysis, exceptional data quality and minimal sample consumption. Using our Proximity Extension Assay (PEA) technology, 1µl samples are analysed for 92 biomarkers simultaneously, with exceptional readout specificity. Disease-focused panels are designed together with leading experts, with full transparency on our rigorous validation data. Proseek Multiplex is available as ready-to-use kits or via our fee-for service offering.

Olink Proteomics


The Antibody Society is a non-profit association representing individuals and organizations involved in antibody research and development. We engage in activities that broadly benefit our members, such as education and publishing, encourage collaboration between companies, academia and government organizations, and help to organize conferences. As a global association, the Society engages with government and international agencies to discuss issues of importance to the antibody community. 


IONTAS offers services for the discovery of antibodies using proprietary Phage Display Technology. Our services draw upon extensive experience in antibody engineering and assay development covering a wide range of targets. Each project is tailored to the specific requirements of each Partner, which facilitates delivery of project objectives in a timely manner. In addition to services, IONTAS develops phage libraries for out-licencing; and is developing other proprietary antibody discovery platforms to generate antibodies against difficult targets.



F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies where the second binding site is in the constant Fc region of an antibody. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim. F-star has currently one programme in the clinic with a second immuno-oncology programme heading toward IND. The company currently employs over 60 people at its research site in Cambridge, UK.



YUMAB’s antibody discovery technology platform provides access to human, natural, close to germline antibody candidates, with low immunogenicity, large epitope diversity, high success rates even for difficult targets like GPCRs, and pre-designed properties like interspecies cross-reactivity or specific epitope targeting. YUMAB antibodies are highly developable for all clinical indications and antibody formats, including full-length IgG and Fab, scFv, bispecifics, chimeric antigen receptors (CARs), antibody fusion proteins and conjugates (ADCs). YUMAB's portfolio covers target discovery, validation and production, personalized patient libraries, optimized antibody discovery solutions and lead development, with flexible fee-for-service solutions and collaborative partnerships.



The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,200 scientists investigate how cancer develops, identify cancer risk factors and work at new strategies to prevent people from getting cancer. They develop novel approaches to make tumour diagnosis more precise and treatment of cancer patients more successful.




CDI Laboratories produces the largest protein microarray available.  CDI’s HuProtTM array contains ~75% of the human proteome. CDI Laboratories sells the HuProtTM as a standalone product as well as used in the following services: biomarker discovery in oncology and autoimmune disease, predictive diagnostic assay development, autoimmune profiling, protein interactome assays. CDI participated in the NIH Protein Capture Reagents Program and has produced ~ 1500 monoclonal antibodies all tested for cross reactivity against HuProtTM. Journals and funding agencies are increasing their standards regarding the reagents used. CDI can produce truly monospecific antibodies to meet these new standards and concerns.

Nextgen Proteomics



The Jackson Laboratory is a leading provider of a wide range of mouse models and services for immunology, immuno-oncology, autoimmunity, and inflammation research.   Drawing on decades of research experience, we provide capabilities around mouse model selection and husbandry to help clients and researchers evaluate novel therapies. Learn more at


Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. We provide web-based, digital solutions — among them ScienceDirectScopusEvolve, KnovelReaxys and ClinicalKey — and publish over 2,500 journals and more than 33,000 book titles. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.


Next generation tumour-directed immunotherapies.

Alligator develops antibody-based drugs for tumor-directed immunotherapy. The Company is primarily active in the early phases of drug development, from the idea stage until to clinical trials in phase IIa. Alligator’s first clinical asset, ADC-1013, is an agonistic antibody targeting the CD40 receptor. It is currently in clinical phase I in cancer patients and has been licensed to Janssen Biotech. The bispecific antibody Ator-1015 is a first in class immunotherapy targeting OX40 and CTLA-4. It is in preclinical development and will enter clinical phase in the first half of 2018.

Alligator Bioscience


Immunovia (Lund, Sweden) is a life science company focused on developing blood based tests for cancer and autoimmune diseases. Immunovia´s core technology, IMMray™, is based on antibody biomarker microarray analysis. IMMray™ PanCan-d, now undergoing clinical validation, could be the first blood based test for early diagnosis of pancreatic cancer. The company has started a programme focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this programme, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation.



Clinical Laserthermia Systems AB develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). Clinical studies are currently performed in a number of hospitals in Europe for indications such as pancreas, breast and prostate cancer.



Biametrics develops and markets label-free analytical system solutions for life science applications. Our patented label-free SCORE technology includes an innovative detection method, surface chemistry and assay development for time-resolved analysis of any kind of biomolecular interaction. We offer label-free measurement systems from single-channel devices up to high-throughput microarray readers. Together with leading peptide and protein manufacturers we develop specialized tools for applications like autoimmune diseases, cancer research or biologics screening. 


VIB is a life sciences research institute in Flanders, Belgium. More than 1470 scientists from over 66 countries perform basic research into the molecular foundations of life. The institute offers a program of international VIB conferences in various VIB research fields. From day one VIB has supported and sponsored scientific conferences to help VIB scientists network with their colleagues. In 2014 the VIB Conference Series was launched to further expand these activities and support them with a dedicated professional team.